FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293755174> ?p ?o ?g. }

• W4293755174 abstract "Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in mUM. A retrospective cohort of 47 mUM patients, 24 men and 23 women, received nivolumab/ipilimumab between October 2019 and December 2021, mostly first line (94%). Two regimens were used: nivolumab 1 mg/kg + ipilimumab 3 mg/kg (nivo1ipi3, 49% of patients) and nivolumab 3 mg/kg + ipilimumab 1 mg/kg (nivo3ipi1, 51% of patients). Median follow-up was 37 and 88 weeks in nivo3ipi1 and nivo1ipi3 cohorts, respectively. We observed partial response in two patients (4%) and stable disease in 14 patients (30%), with no significant difference between the two regimens. Median progression-free survival was 13.6 weeks and 11.9 weeks in the nivo1ipi3 and nivo3ipi1 cohorts, respectively (p = 0.49). Severe adverse events (grade 3 or 4) were observed in seven patients (15%) among which five treated with nivo1ipi3 (22%) and two treated with nivo3ipi1 (8%). These data suggest that nivolumab/ipilimumab combination does not improve clinical outcomes compared to other therapies but is more toxic. In the absence of controlled clinical trials, we would not recommend this combination as a standard treatment in all mUM patients but rather as an option. Patients for whom the benefit-risk ratio could justify the combination need to be defined." @default.
• W4293755174 created "2022-08-31" @default.
• W4293755174 creator A5003132941 @default.
• W4293755174 creator A5003364375 @default.
• W4293755174 creator A5003536346 @default.
• W4293755174 creator A5010683839 @default.
• W4293755174 creator A5015994748 @default.
• W4293755174 creator A5018287918 @default.
• W4293755174 creator A5026943609 @default.
• W4293755174 creator A5044926681 @default.
• W4293755174 creator A5049445132 @default.
• W4293755174 creator A5066983589 @default.
• W4293755174 creator A5088213389 @default.
• W4293755174 date "2022-08-31" @default.
• W4293755174 modified "2023-10-01" @default.
• W4293755174 title "Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients" @default.
• W4293755174 cites W2348355335 @default.
• W4293755174 cites W2745658163 @default.
• W4293755174 cites W2748716584 @default.
• W4293755174 cites W2792937256 @default.
• W4293755174 cites W2896600825 @default.
• W4293755174 cites W2915708315 @default.
• W4293755174 cites W2947820344 @default.
• W4293755174 cites W2949122086 @default.
• W4293755174 cites W2952991175 @default.
• W4293755174 cites W2976744492 @default.
• W4293755174 cites W2984462607 @default.
• W4293755174 cites W3038039573 @default.
• W4293755174 cites W3096267580 @default.
• W4293755174 cites W3119086885 @default.
• W4293755174 cites W3120989185 @default.
• W4293755174 cites W3200574709 @default.
• W4293755174 cites W4206773095 @default.
• W4293755174 cites W4285792224 @default.
• W4293755174 doi "https://doi.org/10.1080/2162402x.2022.2116845" @default.
• W4293755174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36092639" @default.
• W4293755174 hasPublicationYear "2022" @default.
• W4293755174 type Work @default.
• W4293755174 citedByCount "4" @default.
• W4293755174 countsByYear W42937551742023 @default.
• W4293755174 crossrefType "journal-article" @default.
• W4293755174 hasAuthorship W4293755174A5003132941 @default.
• W4293755174 hasAuthorship W4293755174A5003364375 @default.
• W4293755174 hasAuthorship W4293755174A5003536346 @default.
• W4293755174 hasAuthorship W4293755174A5010683839 @default.
• W4293755174 hasAuthorship W4293755174A5015994748 @default.
• W4293755174 hasAuthorship W4293755174A5018287918 @default.
• W4293755174 hasAuthorship W4293755174A5026943609 @default.
• W4293755174 hasAuthorship W4293755174A5044926681 @default.
• W4293755174 hasAuthorship W4293755174A5049445132 @default.
• W4293755174 hasAuthorship W4293755174A5066983589 @default.
• W4293755174 hasAuthorship W4293755174A5088213389 @default.
• W4293755174 hasBestOaLocation W42937551741 @default.
• W4293755174 hasConcept C121608353 @default.
• W4293755174 hasConcept C126322002 @default.
• W4293755174 hasConcept C141071460 @default.
• W4293755174 hasConcept C143998085 @default.
• W4293755174 hasConcept C167135981 @default.
• W4293755174 hasConcept C197934379 @default.
• W4293755174 hasConcept C2777658100 @default.
• W4293755174 hasConcept C2777701055 @default.
• W4293755174 hasConcept C2780030458 @default.
• W4293755174 hasConcept C2781433595 @default.
• W4293755174 hasConcept C2994587330 @default.
• W4293755174 hasConcept C502942594 @default.
• W4293755174 hasConcept C535046627 @default.
• W4293755174 hasConcept C71924100 @default.
• W4293755174 hasConcept C72563966 @default.
• W4293755174 hasConceptScore W4293755174C121608353 @default.
• W4293755174 hasConceptScore W4293755174C126322002 @default.
• W4293755174 hasConceptScore W4293755174C141071460 @default.
• W4293755174 hasConceptScore W4293755174C143998085 @default.
• W4293755174 hasConceptScore W4293755174C167135981 @default.
• W4293755174 hasConceptScore W4293755174C197934379 @default.
• W4293755174 hasConceptScore W4293755174C2777658100 @default.
• W4293755174 hasConceptScore W4293755174C2777701055 @default.
• W4293755174 hasConceptScore W4293755174C2780030458 @default.
• W4293755174 hasConceptScore W4293755174C2781433595 @default.
• W4293755174 hasConceptScore W4293755174C2994587330 @default.
• W4293755174 hasConceptScore W4293755174C502942594 @default.
• W4293755174 hasConceptScore W4293755174C535046627 @default.
• W4293755174 hasConceptScore W4293755174C71924100 @default.
• W4293755174 hasConceptScore W4293755174C72563966 @default.
• W4293755174 hasFunder F4320320893 @default.
• W4293755174 hasIssue "1" @default.
• W4293755174 hasLocation W42937551741 @default.
• W4293755174 hasLocation W42937551742 @default.
• W4293755174 hasLocation W42937551743 @default.
• W4293755174 hasLocation W42937551744 @default.
• W4293755174 hasLocation W42937551745 @default.
• W4293755174 hasOpenAccess W4293755174 @default.
• W4293755174 hasPrimaryLocation W42937551741 @default.
• W4293755174 hasRelatedWork W2429247496 @default.
• W4293755174 hasRelatedWork W2745358348 @default.
• W4293755174 hasRelatedWork W2783842152 @default.
• W4293755174 hasRelatedWork W2888298425 @default.
• W4293755174 hasRelatedWork W2891051134 @default.
• W4293755174 hasRelatedWork W2899127460 @default.
• W4293755174 hasRelatedWork W2963333658 @default.
• W4293755174 hasRelatedWork W3213713949 @default.

• next